Biopharma is exploring the possibility of building a new plant by 2027, the company’s president Konstantin Efimenko said.
“We have already processed almost 300 thousand liters of plasma, the company’s turnover is slightly more than $100 million, and we need to triple the company’s turnover in four years. But it will not be possible to increase capacity further, we need to build a new plant. The new plant should be ready by 2027. To make it ready by 2027, we need to start tomorrow,” he said during the forum “Dialogues on Sustainability. How Business Develops in Times of War” forum in Kyiv on Thursday.
Efymenko also said that Biopharma plans to build a plant in Romania, but this is not a strategy to reduce dependence on Ukraine, but a way to “increase turnover.”
At the same time, Efimenko noted that attracting investments to Ukraine is currently hampered, in particular, by the issues of war risk insurance and the withdrawal of dividends.
“Biopharma is concerned about this issue, but not so much, because we are here with the foundation of the White Church, with the land. We are already here and will be here. But I am worried about other investors coming here, because the question will arise who needs our country,” he said.
As reported, Biopharma plans to triple the number of its plasma centers to 30 by 2027.
